<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021669</url>
  </required_header>
  <id_info>
    <org_study_id>201309002</org_study_id>
    <secondary_id>R01HL117805</secondary_id>
    <nct_id>NCT02021669</nct_id>
  </id_info>
  <brief_title>Omega-3 for Depression and Other Cardiac Risk Factors - 2</brief_title>
  <acronym>Omega-3(2)</acronym>
  <official_title>Omega-3 for Depression and Other Cardiac Risk Factors-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to
      determine whether antidepressant augmentation with two grams of EPA omega-3 per day is
      superior to antidepressant therapy alone for major depression in patients with coronary heart
      disease (CHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression increases the risk for cardiac morbidity and mortality 2-4 fold in patients with
      coronary heart disease (CHD). Recent clinical trials have tested standard treatments for
      comorbid depression in patients with CHD, and some have evaluated their effects on cardiac
      morbidity and mortality. Most of these trials have shown that standard treatments have only
      modest effects on depression and have produced relatively small differences between the
      intervention and control condition. Consequently, they have been unable to determine whether
      effective treatment of depression can improve cardiac outcomes. Low dietary intake and low
      plasma phospholipid or erythrocyte levels of two omega-3 fatty acids(FAs), eicosapentaenoic
      acid (EPA) and docosahexaenoic acid (DHA), are associated with depression and other cardiac
      risk markers. There is growing evidence from small psychiatric trials that the efficacy of
      standard antidepressants can be improved by coadministration of an omega-3 FA formulation
      containing at least 1 gram of EPA. The purpose of the proposed research is to determine
      whether antidepressant augmentation with this omega-3 formulation is superior to
      antidepressant therapy alone for major depression in patients with CHD. The proposed study is
      a randomized, placebo-controlled, double-blind clinical trial. Consenting patients with
      established coronary heart disease who meet the Diagnostic Statistical Manual (DSM)-5
      criteria for a major depressive episode will undergo a baseline evaluation and then be
      randomly assigned to receive either 50 mg/day of sertraline plus omega-3 FA or 50 mg/day of
      sertraline plus placebo for 10 weeks. At baseline and after 10 weeks, participants will
      complete assessments of depression, 24 hour ambulatory ECG monitoring to measure 24 hour
      heart rate and heart rate variability, and blood draws to measure procoagulant and
      proinflammatory markers and blood levels of EPA, DHA, other omega-3 FAs, and the omega-6 FAs.
      If sertraline plus this omega-3 formulation significantly reduces depression compared to
      sertraline plus placebo, and if it improves or at least does not worsen other cardiovascular
      risk markers, this study will provide a strong basis for proposing a multicenter clinical
      trial of sertraline augmented with omega-3 to determine whether treatment of depression can
      improve survival in patients with CHD and depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2014</start_date>
  <completion_date type="Actual">September 13, 2018</completion_date>
  <primary_completion_date type="Actual">September 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>Change from baseline to 10 weeks (post-treatment)</time_frame>
    <description>The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D, 17)</measure>
    <time_frame>Change from baseline to 10 weeks (post-treatment)</time_frame>
    <description>The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Omega-3 supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 supplement</intervention_name>
    <description>Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks</description>
    <arm_group_label>Omega-3 supplement</arm_group_label>
    <other_name>EPA Plus Minami Nutrition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented coronary heart disease

          -  Diagnosis of major depression based on structured interview

        Exclusion Criteria:

          -  Moderate to severe cognitive impairment

          -  Meets DSM-5 criteria for depressive disorder due to a general medical condition or
             medication

          -  Major Axis I psychiatric disorder other than unipolar depression or an anxiety
             disorder, a high risk of suicide, or current substance abuse other than tobacco;

          -  Not expected to survive one year or physically unable to tolerate the study protocol

          -  Known sensitivity to sertraline or omega-3, or an allergy to fish oil or shellfish

          -  Taking an antidepressant or an omega-3 supplement at baseline

          -  Exempted by their cardiologist or primary care physician

          -  Refuses to provide informed consent

          -  Participating in a competing protocol or trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Carney, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <results_first_submitted>July 12, 2019</results_first_submitted>
  <results_first_submitted_qc>July 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2019</results_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antidepressive agents</keyword>
  <keyword>Coronary disease</keyword>
  <keyword>Depression</keyword>
  <keyword>Depressive disorder</keyword>
  <keyword>Fatty Acids, Omega-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02021669/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omega-3 Supplement</title>
          <description>Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
Omega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Placebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omega-3 Supplement</title>
          <description>Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
Omega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Placebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="9.6"/>
                    <measurement group_id="B2" value="60.5" spread="9.3"/>
                    <measurement group_id="B3" value="59.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Beck Depression Inventory-II (BDI-II)</title>
        <description>The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.</description>
        <time_frame>Change from baseline to 10 weeks (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Supplement</title>
            <description>Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
Omega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Placebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory-II (BDI-II)</title>
          <description>The BDI-II is a 21-item self-report inventory of depression symptoms. The minimum and maximum values for the BDI-II are (0-63). For both instruments, the higher the scores, the greater the severity of depression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="9.0"/>
                    <measurement group_id="O2" value="29.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Treatment (10 Weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="9.9"/>
                    <measurement group_id="O2" value="9.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale (HAM-D, 17)</title>
        <description>The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.</description>
        <time_frame>Change from baseline to 10 weeks (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Supplement</title>
            <description>Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
Omega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Placebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HAM-D, 17)</title>
          <description>The HAM-D, 17 is a 17-item, observer-rated measure of depression symptoms. The minimum and maximum values for the HAM-D, (0-52). For both instruments, the higher the scores, the greater the severity of depression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="5.4"/>
                    <measurement group_id="O2" value="17.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Treatment (10 Weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="7.0"/>
                    <measurement group_id="O2" value="6.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each participant was followed for fourteen weeks (ten weeks of treatment plus a final call 4 weeks after the end of treatment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omega-3 Supplement</title>
          <description>Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
Omega-3 supplement: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Placebo: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Increased flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Burping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Increased sleepiness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Decreased sexual interest/performance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Increased sweating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Bad taste in mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hand Tremors</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Increased anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Less emotionally responsive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert M. Carney, Ph.D</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-286-1305</phone>
      <email>carneyr@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

